| Objective:The study was conducted to observe the effects of the TCM care-based Tiaoshen Yizhi acupuncture on the cognitive function,daily living ability,quality of life,and blood biochemical indexes of patients with mild to moderate Alzheimer’s disease,and to comprehensively evaluate the clinical efficacy and safety of this method on mild to moderate AD.Methods:The study was a randomized controlled trial.Fifty-two patients with mild to moderate AD were randomly divided into experimental and control groups,26 patients in each group.All patients received conventional treatment for AD,and the control group used TCM nursing intervention,while the experimental group added the Tiaoshen Yizhi acupuncture intervention on top of the control group.Patients in both groups were scored on the Simple Mental State Examination Scale(MMSE),the Ability to Perform Daily Living Scale(ADL),and the Quality of Life in Alzheimer’s Disease Scale(QOL-AD)before the intervention,at week 6,and at the end of week 12,respectively;and early morning fasting venous blood was collected before the intervention and at the end of week 12,and serum interleukin-6(IL-6)and interleukin-1β(IL-1β)were measured.Interleukin-1β(IL-1β)levels were measured.Results:1.Cognitive ability: Both the control and experimental groups were able to improve the MMSE scores of AD patients,and the difference was statistically significant(P < 0.05);intra-group comparison: at 6 weeks of treatment,the orientation scores of both groups improved compared with baseline,and the difference was statistically significant(P < 0.05);at 12 weeks of treatment,the total MMSE scores,orientation and memory scores of both groups improved compared with those at 6weeks of intervention,and the difference was statistically significant(P < 0.05);comparison between groups: at baseline,there was no significant difference in the total MMSE score and each dimension score between the two groups,(P > 0.05),at 6 weeks of treatment,the orientation score of the experimental group was higher than that of the control group,and the difference was statistically significant(P < 0.05),at 12 weeks of treatment,the total MMSE score,orientation and memory scores of the experimental group were higher than those of the control group,and the differences were statistically significant(P < 0.05).2.Bility to perform daily living: Both control and experimental groups were able to improve ADL scores of AD patients,and the difference was statistically significant(P < 0.05);intra-group comparison: the scores of experimental group were higher than those at the previous evaluation time point,and the difference was statistically significant(P < 0.05),control group: compared with baseline,at 12 weeks of treatment,the difference was statistically significant(P<0.05);inter-group comparison: at baseline,6 weeks of treatment At week,there was no significant difference in ADL scores between the two groups(P>0.05),and at 12 weeks of treatment,the scores in the experimental group were higher than those in the control group,and the difference was statistically significant(P < 0.05).3.Quality of life: Both the control group and the experimental group were able to improve the QOL-AD scores of AD patients,and the difference was statistically significant(P < 0.05);intra-group comparison: the scores of both groups were higher than the scores at the previous evaluation point within the group,and the difference was statistically significant(P < 0.05);inter-group comparison: at baseline and 6 weeks of treatment,there was no significant difference in QOL-AD scores(P > 0.05),and at 12 weeks of treatment The difference was statistically significant(P < 0.05).4.Comparison of inflammatory factor levels: Before treatment,there was no statistically significant difference in serum IL-6 and IL-1β levels between patients in the control and experimental groups(p>0.05).After 12 weeks of treatment,the serum IL-6and IL-1β levels in both groups,compared with those before treatment,were lower than those before treatment(p < 0.05),and the IL-6 and IL-1β levels in the experimental group were lower than those in the control group,and the differences were statistically significant(p < 0.05).5.Safety evaluation: Patients in both groups were in stable condition during the treatment,the incidence of adverse reactions in the experimental group and the control group were 7.96% and 3.85% respectively,the incidence of adverse reactions in the experimental group was slightly higher than that in the control group,and the difference was not statistically significant.Conclusion:The Tiaoshen Yizhi acupuncture based on TCM care has good clinical efficacy in treating patients with mild to moderate AD,and is safe and reliable;it can improve patients’ MMSE,ADL and QOL-AD scores,and reduce serum inflammatory factor levels,effectively improve patients’ cognitive function,daily living ability and quality of life,and suppress inflammatory reactions. |
PDF Full Text Request